Integral dose in moving-beam irradiation. 1959

F O'FOGHLUDHA

UI MeSH Term Description Entries
D011878 Radiotherapy The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions. Radiotherapy, Targeted,Targeted Radiotherapy,Radiation Therapy,Radiation Therapy, Targeted,Radiation Treatment,Targeted Radiation Therapy,Radiation Therapies,Radiation Therapies, Targeted,Radiation Treatments,Radiotherapies,Radiotherapies, Targeted,Targeted Radiation Therapies,Targeted Radiotherapies,Therapies, Radiation,Therapies, Targeted Radiation,Therapy, Radiation,Therapy, Targeted Radiation,Treatment, Radiation
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

F O'FOGHLUDHA
January 1962, The Journal of the Egyptian Medical Association,
F O'FOGHLUDHA
October 1957, Strahlentherapie,
F O'FOGHLUDHA
September 1957, Strahlentherapie,
F O'FOGHLUDHA
October 1954, Medizinische Monatsschrift,
F O'FOGHLUDHA
November 1968, Strahlentherapie,
F O'FOGHLUDHA
January 1956, Strahlentherapie,
F O'FOGHLUDHA
July 1976, Meditsinskaia radiologiia,
F O'FOGHLUDHA
January 1965, Radiobiologia, radiotherapia,
Copied contents to your clipboard!